ArticleBMC infectious diseases2026
Body mass index (BMI) at RR-TB diagnosis as an independent predictor of treatment outcomes: a retrospective analysis.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRifampicin-resistant tuberculosis (RR-TB) remains a major public health concern, particularly in African populations where undernutrition is common. Many participants with RR-TB initiate treatment with a low body mass index (BMI), which has been linked to higher mortality and treatment failure.
methodsThis retrospective study analysed data from 895 participants diagnosed with rifampicin-resistant tuberculosis (RR-TB) enrolled across five clinical trials conducted between 2009 and 2024 in KwaZulu Natal, South Africa. Participants were classified by BMI (normal weight, overweight, and underweight). Cox proportional hazards regression models assessed the relationship between baseline BMI and treatment outcomes, adjusting for potential confounders.
resultsAt baseline, 51% (542/894) of the participants had a normal weight, 16% were overweight, and 34% were underweight. The majority were people living with HIV (PLWHA) (85%) (761/895); 89% (675/761) were on ART, and 51% (240/475) had a suppressed viral load. At day 400, underweight participants had a higher mortality rate per 100 person-years (14.86, 95% CI: 8.13-24.94) compared to those with normal weight (6.27, 95% CI: 3.00-11.52) and overweight individuals (2.06, 95% CI: 0.05-11.50). Underweight participants had an increased risk of unfavourable outcomes (HR = 1.85, 95% CI = 1.35-2.53, p < 0.001), while overweight participants had a reduced risk (HR = 0.39, 95% CI = 0.31-0.97, p = 0.040). Unsuppressed viral load (HR = 1.77, 95% CI = 1.14-2.73, p = 0.011) and absence of ART (HR = 3.00, 95% CI = 1.62-5.55, p < 0.001) were significant risk factors.
conclusionLow BMI is a strong predictor of poor treatment outcomes for RR-TB. Nutritional assessment and interventions should be integrated into RR-TB management procedures to improve patient outcomes.
trial registrationNot applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.